PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Investing in Drug Delivery Technologies: Fighting Patent Expiries - Combating losses due to patent expiries has become a high priority for pharmaceutical companies
Investing in Drug Delivery Technologies: Fighting Patent Expiries

 

NewswireToday - /newswire/ - London, United Kingdom, 2008/09/18 - Combating losses due to patent expiries has become a high priority for pharmaceutical companies.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Investing in new drug delivery technologies is becoming a critical strategy for them to maintain a strong presence in this cut-throat market as they offer the potential to enhance the life cycle of established drugs.

A number of drug delivery, pharmaceutical and biotechnology companies are allocating significant resources towards the development of novel drug delivery systems. Once a small market, the drug delivery market is now poised for significant growth and holds great opportunities for both current players and new entrants.

"The global drug delivery market has witnessed encouraging growth in the past and is forecasted to gain significant importance in the coming years," notes Frost & Sullivan (healthcare.frost.com) Industry Analyst Sylvia Miriyam Findlay. "Heightened competition, the need to maximise revenues and combating patent expiries have forced pharmaceutical companies roll up their sleeves and seek out novel drug delivery systems."

Though the drug delivery market is dominated by oral forms of drugs (52 per cent of the market), other methods, particularly the non-invasive forms – pulmonary, transdermal and nanotechnology – are growing at a rapid pace.

The systemic delivery of drugs through pulmonary means has been the subject of significant research in the medical community. No longer confined to the treatment of respiratory diseases, the successes of dry powder inhalation have pushed the inhalation market to a new level.

Trasndermal drug delivery has also been gaining momentum as certain applications, such as contraceptive patches, have been found to be as effective as their oral counterparts. Cancer pain medication - Fentanyl - has been delivered transdermally and has witnessed increased uptake because of its convenience. Neurological and diabetes medications are other therapeutic drugs that are being investigated for transdermal drug delivery.

One of the most promising areas in drug delivery is nanotechnology. Nano-enabled drug delivery offers tremendous advantages over the current forms of drug delivery such as enhanced solubility, commendable bio-availability, better targeting and controlled delivery.

"The Nanotechnology-based drug delivery market is expected to garner $700-$800 billion revenues by 2015," says Findlay. "The market will be driven by the expanding horizon of therapeutic applications. Venture capital investments in nanotechnology drug delivery companies have been increasing and have therefore provided a positive spin to the market growth."

For many pharmaceutical and biotechnology companies, forging alliances with pure-play drug delivery companies offer the best opportunities to gain access to novel technologies. This can become a crucial strategy for pharmaceutical players to hold onto their market presence.

"Frost & Sullivan's analysis reveals that pharmaceutical companies look for various parameters before forging alliances with drug delivery companies," Findlay says. "A technological edge is most critical, as novel drug delivery methods should focus on providing the maximum patient benefits in addition to having commercial viability."

Frost & Sullivan believes that continuous research efforts in the area of drug delivery will enable the production of novel drug/device combinations. In addition, the future is bound to witness advancements in protein delivery through oral, nasal, buccal, pulmonary and transdermal delivery systems.

If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the European drug delivery market-opportunity analysis, then send an email to Patrick Cairns, Corporate Communications, at pcairns_pr[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by email.

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership™ empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Investing in Drug Delivery Technologies: Fighting Patent Expiries

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Patrick Cairns 
+27 18 468 2315 patrick.cairns[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Ipsen Announces Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival
First Patient Treated with Microscopic Beads Pre-loaded with A Targeted Cancer Drug and Visible on CT Scans
BTG Plc Acquires Roxwood Medical
BTG and Mirada Medical Sign Three-Year Software Development Agreement
U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  SKS Media | SKS Associates Ltd

Visit  RightITnow Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)